Neoadjuvant QL1706 therapy for esophageal cancer before surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug, QL1706, given before surgery for esophageal squamous cell cancer. The goal is to see if it helps shrink tumors and improve outcomes for patients who are healthy enough for the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with esophageal squamous cell cancer that has spread to nearby lymph nodes or is locally advanced, but not to distant organs.
- Your doctor plans to do surgery after you finish neoadjuvant therapy.
- You are in good enough health to perform daily activities on your own (ECOG performance status 0 or 1).
- You do not have active autoimmune diseases, serious heart conditions, or uncontrolled bleeding risks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (Iparomlimab and Tuvonralimab, combined as QL1706) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced stomach or gastroesophageal junction cancer that can be surgically removed.
This trial tests whether adding an immunotherapy drug (QL1706) to standard chemotherapy before surgery can improve outcomes for people with esophageal cancer that can be removed. The goal is to see if the combination shrinks tumors more effectively and is safe.
This trial is testing a new immunotherapy drug (QL1706) combined with an anti-inflammatory drug (celecoxib) for advanced esophageal cancer that has progressed after previous immunotherapy. It may help slow down tumor growth and give you more treatment options.
This study tests a new treatment for people with locally advanced esophageal cancer that did not respond to initial chemotherapy and immunotherapy. The goal is to see if the study drug can shrink or control the cancer when surgery is not an option.
This trial tests a new combination of two drugs (QL1706 and lenvatinib) for people whose esophageal cancer has progressed after initial immunotherapy. The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests whether giving a combination of two immunotherapy drugs, a targeted therapy, and chemotherapy before surgery helps shrink esophageal tumors and improve outcomes. It might make surgery more effective for patients with resectable esophageal cancer.
Hear when a new Locally Advanced Resectable Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.